Dr. Christine Brown is a faculty member in the Departments of Hematology & Hematopoietic Cell Transplantation and Immuno-Oncology.
As Associate Director of the T Cell Therapeutics Research Laboratory (TCTRL), Dr. Brown provides scientific oversight for the pre-clinical research program, as well as the ongoing clinical trial program focused on the development of chimeric antigen receptor (CAR)-engineered T cells for the treatment of hematological malignancies and solid tumors. Dr. Brown’s personal research efforts are focused on developing and refining re-directed CAR T cells for the treatment of malignant brain tumors.
Dr. Brown received her doctoral degree from the University of California, Berkeley, and was a Leukemia & Lymphoma Scholar during her post-doctoral fellowship at Pennsylvania State University. Her scientific contributions to the development and optimization of tumor-specific CAR T cells for the treatment of glioblastoma are supported by the California Institute for Regenerative Medicine (CIRM) and are the basis of an on-going phase I clinical trial which is supported by Gateway for Cancer Research and R01 FD005129.
My research is focused on the development of chimeric antigen receptor (CAR) T cell therapy for the treatment of cancer. I conceptualize, perform and oversee studies to evaluate CAR design, T cell manufacturing, cell-based immunological assays and in vivo animal models. My primary independent research efforts are focused on the development of CAR T cell therapy for the treatment of primary and metastatic brain tumors.
As Associate Director of the T cell Therapeutics Research Laboratory (TCTRL), I also lead multi-functional teams to translate these therapies to the clinical, participating in all stages of the regulatory process.
October 26, 2015
February 16, 2015
January 27, 2015
February 03, 2014
Information listed here is obtained from Pubmed, a public database; City of Hope is not responsible for its accuracy. View all publications.